Rölli, Matthias Andreas

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: Yes

Yes

El Mokh, Oussama; Taelmann, Vincent; Radojewski, Piotr; Rölli, Matthias Andreas; Stooss, Amandine; Dumont, Rebecca A; Dettmer, Matthias; Phillips, Wayne; Walter, Martin Alexander; Charles, Roch-Philippe (2019). MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer. Journal of nuclear medicine, 60(7), pp. 917-923. Society of Nuclear Medicine 10.2967/jnumed.118.216721

Schürch, Christian M; Rölli, Matthias A.; Forster, Stefan; Wasmer, Marie-Hélène; Brühl, Frido; Maire, Renaud S.; Di Pancrazio, Sergio; Ruepp, Marc-David; Giger, Roland; Perren, Aurel; Schmitt, Anja M.; Krebs, Philippe; Charles, Roch-Philippe; Dettmer, Matthias S. (2019). Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid, 29(7), pp. 979-992. Mary Ann Liebert 10.1089/thy.2018.0555

Poirier, Marion; Awale, Mahendra; Rölli, Matthias A.; Giuffredi, Guy T.; Ruddigkeit, Lars; Evensen, Lasse; Stooss, Amandine; Calarco, Serafina; Lorens, James B.; Charles, Roch-Philippe; Reymond, Jean-Louis (2018). Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem, 14(2), pp. 224-236. Wiley-VCH 10.1002/cmdc.201800554

Rölli, Matthias Andreas; Ruffieux-Daidiée, Dorothée; Stooss, Amandine; El Mokh, Oussama; Phillips, Wayne A; Dettmer, Matthias; Charles, Roch-Philippe (2017). PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. OncoTarget, 8(61), pp. 103207-103222. Impact Journals LLC 10.18632/oncotarget.21732

El Mokh, Oussama; Ruffieux-Daidié, Dorothée; Rölli, Matthias Andreas; Stooss, Amandine; Phillips, Wayne A; Gertsch, Jürg; Dettmer, Matthias; Charles, Roch-Philippe (2017). Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo. OncoTarget, 8(15), pp. 24604-24620. Impact Journals LLC 10.18632/oncotarget.15599

Provide Feedback